Alefacept in the treatment of psoriasis
H Sugiyama, TS McCormick, KD Cooper… - Clinics in …, 2008 - Elsevier
Alefacept is the first biologic agent approved by the US Food and Drug Administration for the
treatment of psoriasis. To date, more than 1000 patients with moderate to severe psoriasis
have been enrolled in phase III clinical trials of alefacept. More than 30% of patients treated
with 2 courses of alefacept reached a Physician's Global Assessment of clear to almost
clear, and approximately 40% and 70% of patients achieved a Psoriasis Area Severity Index
score of 75 and 50 after the same regimen. Alefacept is well tolerated, and there have been …
treatment of psoriasis. To date, more than 1000 patients with moderate to severe psoriasis
have been enrolled in phase III clinical trials of alefacept. More than 30% of patients treated
with 2 courses of alefacept reached a Physician's Global Assessment of clear to almost
clear, and approximately 40% and 70% of patients achieved a Psoriasis Area Severity Index
score of 75 and 50 after the same regimen. Alefacept is well tolerated, and there have been …
